000			nab a22 7a 4500
999			_c16921 _d16921
003			PC16921
005			20220622092536.0
008			220621b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92597 _aMartinez-Flores, Jose A. _eInstituto de Investigación i+12
100			_92598 _aSerrano, Manuel _eInstituto de Investigación i+12
100			_92937 _aPérez Méndez, Dolores _eInmunología
100			_9821 _aLora Pablos, David _eInstituto Investigación I+12
100			_91510 _aPaz Artal, Estela _eInmunología
100			_93071 _aMorales, José M. _eInstituto de Investigación imas12
100			_9661 _aSerrano Hernández, Antonio _eInmunología
245	0	0	_aDetection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. _h[artículo]
260			_bJournal of immunological methods, _c2015
300			_a422:51-8.
500			_aFormato Vancouver: Martínez Flores JA, Serrano M, Pérez D, Lora D, Paz Artal E, Morales JM et al. Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. J Immunol Methods. 2015 Jul;422:51-8.
501			_a PMID: 25865263
504			_aContiene 38 referencias
520			_aBackground: Patients with antiphospholipid syndrome (APS) have a hypercoagulable condition associated with the presence of antiphospholipid autoantibodies (aPL). Consensus antibodies for diagnosis are lupus anticoagulant, anti-beta2 glycoprotein I (B2GPI) and anticardiolipin (IgG or IgM). Circulating immunocomplexes (CIC) of B2GPI associated with IgM or IgG were reported. Isolated IgA aB2GPI antibodies have achieved high diagnostic value although specific CIC of B2GPI bounded to IgA (B2A-CIC) has still not been described. CIC detection assays are mainly based on interaction with complement and are not appropriate to detect B2A-CIC because IgA does not fix complement using the classical pathway. Patients and methods: Sera from healthy blood donors (N= 247) and from patients with thrombosis background and isolate positive for IgA aB2GPI (N = 68) were studied in a case-control study. Two methods were applied, these being a capture ELISA to quantify specific B2A-CIC and quantification of total IgA anti-B2GPI after dissociating CIC. Results: B2A-CIC values in APS-patients were 19.27 ± 2.6 AU vs 6.1 ± 0.4 AU in blood donors (p < 0.001). There were 36.4% B2A-CIC positive patients (cutoff 21 AU) versus 5.5% in blood donors (p < 0.001). Dissociated IgA aB2GPI levels (total IgA aB2GPI) were 146.8 ± 10.8 IU/mL in patients vs. 22.4 IU/mL in controls (p < 0.001). B2A-CIC was independent of B2GPI and autoantibodies IgA aB2GPI serum levels. Conclusion: B2A-CIC can be identified and quantified in an easy and reproducible manner using two complement-independent methods. The use of these tests in prospective studies will allow better understanding of the prognosis and outcome of patients.
710			_9625 _aInstituto de Investigación imas12
710			_9395 _aServicio de Inmunología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16921.pdf _ySolicitar documento
942			_2ddc _cART _n0